BST Update
BST Position Update: October 3, 2014
October 3, 2014 . . . . Argos Therapeutics (NASDAQ: ARGS) – Buy Our most recent trade has started off on a positive note. ARGS has been trending higher since our recommendation went out. At a current price of $9.77, it’s currently up 8% and just below our $10.00 buy up to price. The company […]
BST Position Update: July 23, 2014
July 23, 2014 . . . . Rigel Pharmaceuticals (NASDAQ: RIGL) – Hold Our most recent addition to the portfolio is off to a great start. RIGL has traded up to our maximum buy price in just two trading days since our recommendation was released. That’s exactly what we like to see. Now there hasn’t […]
BST Position Update: June 25, 2014
June 25, 2014 . . . . GTx (NASDAQ: GTXI) – Sell GTXI has been a huge disappointment. We were hoping the shares would pop on the results of the phase 2 trial of enobosarm 9mg in patients with metastatic breast cancer. But after a small bump, the stock has come right back down. With […]
BST Position Update: June 3, 2014
June 3, 2014 . . . . Xencor (NASDAQ: XNCR) – Buy up to $9.40 XNCR is our latest addition to the portfolio. This exciting clinical stage biotech is developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. We like Xencor for several reasons… Its proprietary drug development […]
BST Position Update: May 1, 2014
May 1, 2014 It’s been a rough couple of months for the Biotech sector. Look no further than a chart of the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) to see what I mean. Since hitting a high of 275.40 on February 25th, IBB has lost nearly 16% of its value. And at the low of 207.48 […]
BST Special Position Update: April 2, 2014
April 2, 2014 ***Special Position Update***. . . . Prana Biotechnology (NASDAQ: PRAN) – Hold Shares of PRAN have plunged more than 75% over the past couple of days. The stock is down after the biotech reported disappointing top-line results from the phase 2 trial of PBT2 in Alzheimer’s disease. The drug failed to […]
BST Position Update: March 25, 2014
March 25, 2014 . . . . Cerus (NASDAQ: CERS) – Buy up to $6.60 CERS is our latest addition to the portfolio. They’re developing the INTERCEPT Blood System which is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. While we have high expectations for CERS, the timing of our trade […]
BST Position Update: March 11, 2014
March 11, 2014 . . . . Lpath (NASDAQ: LPTN) – Buy up to $5.30 LPTN was added to the portfolio a few days ago. This fascinating biotech is pioneering a new approach to drug development using lipidomics and its ImmuneY2 technology. The company’s leading drug candidate is a monoclonal antibody called iSONEP that is […]
BST Position Update: February 26, 2014
February 26, 2014 . . . . Acasti Pharma (NASDAQ: ACST) – Buy up to $1.40 Acasti is our most recent addition to the portfolio. This exciting biotech is developing CaPre for the prevention and treatment of hypertriglyceridemia. CaPre is a highly purified omega-3 phospholipid concentrate derived from krill oil. We’re excited about CaPre because […]
BST Position Update: February 12, 2014
February 12, 2014 Biotech Market Update: The biotech sector put in an amazing performance in 2013. One look at a chart of the SPDR S&P Biotech ETF (NYSE: XBI) makes that perfectly clear. As you can see, the sector trended higher for most of the year. It suffered a correction in June and another in October […]
